Table 1.
Baseline clinicopathologic characteristics of patients with first-line treatment
| Clinicopathologic characteristic | Cetuximab group | Chemotherapy alone group | P value d | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| All patients | RSCC | LSCRC | P value | All patients | RSCC | LSCRC | P value | ||||
| No. of patients | 110 | 33 | 77 | – | 117 | 61 | 56 | – | 0.001* | ||
| Median age at diagnosis | 0.420 | 0.502 | 0.613 | ||||||||
| ≤65 years | 90 (81.8) | 29 (87.9) | 62 (80.5) | 93 (79.5) | 50 (82.0) | 43 (76.8) | |||||
| >65 years | 20 (18.2) | 4 (12.1) | 15 (19.5) | 24 (20.5) | 11 (18.0) | 13 (23.2) | |||||
| Sex | 0.274 | 0.085 | 0.404 | ||||||||
| Male | 75 (68.2) | 20 (60.6) | 55 (71.4) | 73 (62.4) | 43 (70.5) | 30 (53.6) | |||||
| Female | 35 (31.8) | 13 (39.4) | 22 (28.6) | 44 (37.6) | 18 (29.5) | 26 (46.4) | |||||
| ECOG performance status | 0.300 | 0.367 | 0.113 | ||||||||
| 0 | 49 (44.5) | 11 (33.3) | 38 (49.4) | 49 (41.9) | 29 (47.5) | 20 (35.7) | |||||
| 1 | 58 (52.7) | 21 (63.6) | 37 (48.1) | 57 (48.7) | 26 (42.6) | 31 (55.4) | |||||
| ≥2 | 3 (2.7) | 1 (3.0) | 2 (2.6) | 11 (9.4) | 6 (9.8) | 5 (8.9) | |||||
| Pathology | 0.003* | 0.116 | 0.608 | ||||||||
| Adenocarcinoma | 101 (91.8) | 26 (78.8) | 75 (97.4) | 110 (94.0) | 55 (90.2) | 55 (98.2) | |||||
| Mucinous & signet-ring cell | 9 (8.2) | 7 (21.2) | 2 (2.6) | 7 (6.0) | 6 (9.8) | 1 (1.8) | |||||
| Metastasis | 0.674 | 0.015* | 0.893 | ||||||||
| Single | 67 (60.9) | 19 (57.6) | 48 (62.3) | 70 (59.8) | 43 (70.5) | 27 (48.2) | |||||
| Multiple | 43 (39.1) | 14 (42.4) | 29 (37.7) | 47 (40.2) | 18 (29.5) | 29 (51.8) | |||||
| Metastasis resection | 29 (26.4) | 6 (18.2) | 23 (29.9) | 0.244 | 28 (23.9) | 15 (24.6) | 13 (23.2) | 1.000 | 0.760 | ||
| Total cycles of cetuximaba | 8 (2–29) | 9 (2–29) | 8 (2–29) | 0.537 | – | – | – | – | – | ||
| Total cycles of chemotherapya | 13 (2–43) | 13 (3–38) | 13 (2–43) | 0.928 | 13 (2–38) | 14 (2–38) | 13 (4–38) | 0.546 | 0.344 | ||
| All three active drugsb | 73 (66.4) | 24 (72.7) | 49 (63.6) | 0.388 | 89 (76.1) | 48 (78.7) | 41 (73.2) | 0.522 | 0.109 | ||
| Backbone chemotherapy | 0.029* | 0.041* | 0.003* | ||||||||
| Oxaliplatin-based | 37 (33.6) | 6 (18.2) | 31 (40.3) | 63 (53.8) | 27 (44.3) | 36 (64.3) | |||||
| Irinotecan-based | 73 (66.4) | 27 (81.8) | 46 (59.7) | 54 (46.2) | 34 (55.7) | 20 (35.7) | |||||
| Bevacizumab during the disease | 44 (40.0) | 15 (45.5) | 29 (37.7) | 0.525 | 38 (32.5) | 24 (39.3) | 14 (25.0) | 0.116 | 0.270 | ||
| Recurrent diseasec | 31 (28.2) | 6 (18.2) | 25 (32.5) | 0.230 | 32 (27.4) | 18 (29.5) | 14 (25.0) | 0.679 | 1.000 | ||
aThe values are presented as median followed by range in parentheses; other values are presented as the number of patients followed by percentages in parentheses. b Patients who received 5-fluorouracil, oxaliplatin, and irinotecan during the course of their disease. c Patients who had metastatic disease after curative-intent primary tumor resection. d Patient characteristics were compared between the cetuximab and chemotherapy groups. ECOG, Eastern Cooperative Oncology Group; RSCC, right-sided colon cancer; LSCRC, left-sided colorectal cancer